Mylan Inc. announced that its subsidiary Mylan Pharmaceuticals Inc. has begun to market 1% Clindamycin and 5% Benzoyl Peroxide gel based on an agreement with licensing partner Dow Pharmaceutical Sciences, a subsidiary of Valeant Pharmaceuticals International. The preparation is the first generic version of sanofi aventis' BenzaClin to be approved by the US Food and Drug Administration (FDA).

On August 11, Dow received FDA approval for its Abbreviated New Drug Application (ANDA) for Clindamycin 1% and Benzoyl Peroxide 5% gel, a prescription-strength topical antibiotic used to treat acne. According to IMS Health, BenzaClin had total US sales of approximately $221 million for the 12 months ending June 30.

Mylan Inc., which provides products to customers in more than 140 countries and territories, ranks among the leading diversified generics and specialty pharmaceutical companies in the world.